Sana Biotechnology's In Vivo CAR T Therapy Shows Promising Preclinical Results in Non-Human Primates
Event summary
- Sana Biotechnology presented preclinical data for SG293, an in vivo CAR T cell therapy, at the ASGCT 2026 Annual Meeting on May 12, 2026.
- SG293 demonstrated cell-specific delivery, robust CAR T cell generation, and deep B cell depletion in NHPs without lymphodepleting chemotherapy.
- The company plans to initiate clinical trials for SG293 in non-Hodgkin lymphoma later in 2026 and for SG227 in multiple myeloma as early as mid-2027.
- SG293's novel transgene design aims to mitigate anti-CAR immunogenicity and improve durability of in vivo CAR T cells.
The big picture
Sana Biotechnology's preclinical data for SG293 highlights the potential of in vivo CAR T cell therapies to offer off-the-shelf treatment options for blood cancers and autoimmune diseases. The company's fusogen platform aims to address key challenges in targeted delivery and immunogenicity, positioning it as a significant player in the evolving landscape of cell-based therapies. The strategic focus on expanding into multiple myeloma and autoimmune diseases underscores the broader market opportunities in oncology and beyond.
What we're watching
- Clinical Translation
- How the preclinical success of SG293 will translate into clinical efficacy and safety in human trials.
- Market Differentiation
- Whether Sana's fusogen platform can provide a sustained competitive advantage in the CAR T cell therapy space.
- Regulatory Pathway
- The pace at which SG293 and SG227 advance through regulatory approvals for oncology and autoimmune indications.
Related topics